A case series of extraneural metastatic glioblastoma at Memorial Sloan Kettering Cancer Center

• DOI: 10.1093/nop/npaa083
• Publication Date: 2021-02-06T04:08:56Z
• Authors: Evan K Noch; Sameer F Sait; Shama Farooq; Tanya M Trippett; Alexandra M Miller
• Keywords: Gliosarcoma; Temozolomide

Extraneural metastasis of glioma is a rare event, often occurring in patients with advanced disease. Genomic alterations associated extraneural remain incompletely understood.Ten at Memorial Sloan Kettering Cancer Center diagnosed metastases glioblastoma (9 patients) and gliosarcoma (1 patient) from 2003 to 2018 were included our analysis. Patient characteristics, clinical course, genomic evaluated.Patient age diagnosis ranged 14 73, 7 men 3 women this group. The median overall survival initial was 19.6 months (range 11.2 57.5 months) 5 1 16.1 months), respectively. most common site bone, other sites being lymph nodes, dura, liver, lung, soft tissues. All received surgical resection radiation, 9 temozolomide, subsequent chemotherapy appropriate for individual cases. patient had an Ommaya then ventriculoperitoneal shunt placed, underwent craniectomy cerebral edema brain abscess the resection. analysis primary tumors metastatic revealed shared private mutations preponderance tumor suppressor gene alterations, illustrating clonal evolution metastases.Several risk factors emerged gliosarcoma, including sarcomatous dedifferentiation, disruption normal anatomic barriers during resection, alterations. Next steps work include validation these markers larger populations development preclinical models. This will lead better understanding molecular mechanisms develop targeted treatments patients.